-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mylan recently announced that it will buy the intellectual property and commercial rights of Aspen Pharmacare's anticoagulants (Arixtra, Fraxiparine, Mon-Embolex and Orgaran) in the European market for $756 million.
terms of the deal, Mylan will pay Aspen $310 million first and $446 million by June 25, 2021, according to the terms of the deal, which is expected to be completed by December 31.
the same period last year, Mylan invested a cumulative net sales of 231 million euros in products during the year.
aspen will continue to manufacture the anticoagulants included in the deal, given its "vertically integrated supply chain" in Europe, Mr. Mylan said in a press release.
acquisition of Aspen products will make Mylan the second largest producer of thrombosis products in Europe and expand its hospital operations.
said it would expand its marketing team to accommodate its growing volume of business, but it was not disclosed how many jobs would be added.
, Mylan is trying to end a delayed merger with Upjohn, Pfizer's generics division.
that the new company after the merger is called Viatris.
announced in July 2019 that Pfizer shareholders would own 57 percent of the combined company and Mylan shareholders would own 43 percent of the combined company.
said the acquisition would not affect the company's ability to repay its debts because viatris' new products would have a positive impact on the company's profits once it companies went public next year.
Mylan has a portfolio of operations in many regions and therapeutic areas, including the central nervous system and anesthesia, infectious diseases and cardiovascular diseases, as well as strong product line pipelines, high-quality manufacturing and supply chains.
Upjohn's main drugs, including Lipitor, Celebrex and Viagra, have strong commercial capabilities in China and other emerging markets.
2020, Viatris, with estimated revenues of $1.9 billion to $20 billion, will be led and executive chairman by Mylan's current chairman, Robert J. Coury, and Michael Goettler, upjohn's current group president.
the merger was originally scheduled to be completed in the second quarter of this year, but the complexity of regulatory approvals delayed the original merger due to the impact of the COVID-19 new crown pneumonia outbreak.
now, the two companies aim to close the merger in the fourth quarter.
a successful merger, Vidias is on track to become the world's largest generic drugmaker.
.